Global Peptide Therapeutics Market (2021 Edition) – Analysis By Drug Type (Generic, Innovative), Manufacturing Type (In-House, Outsourced), Application,, By Region, By Country: Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)
Executive Summary
The Global Peptide Therapeutics Market is valued at USD 32.1 Billion in the year 2020. The growth of Peptide Therapeutics is directly associated with drug development. New drug discovery and product launch in chronic metabolic disorders would provide fruitful opportunities for Peptide Therapeutics Market. The factors such as surging prevalence of cancer, rising healthcare expenditure, growing incidence of metabolic disorders, increasing geriatric population and accelerating number of approved peptide-based therapeutic drugs will facilitate market growth.
New drug discovery and product launch in chronic metabolic disorders expected to provide potential opportunities to Peptide Therapeutics Market, further supported by factors such as surging prevalence of cancer, rising healthcare expenditure, growing incidence of metabolic disorders, increasing geriatric population and accelerating number of approved peptide-based therapeutic drugs. Over the years, the rising popularity of biologics, such as peptide therapeutics, have led to an evident shift in the focus of the healthcare industry, from traditional small molecule-based interventions to upcoming, albeit complex, family of pharmacological interventions.
The success of peptide therapeutics, so far, can be attributed to their clinical benefits, which include high target specificity, low toxicity and favourable safety profiles. Furthermore, with enhanced technologies, the prospects of the peptide drugs are getting influential day by day and new peptides are being discovered to be developed as peptide drug. Peptide therapeutics is completely different from the traditional methods and may open a new window for finding completely new peptide drugs. Moreover, Peptide gives an opportunity for therapeutics intervention that follows natural pathways hence there has been decline in non-peptide chemically synthesized drug discovery as well as rise in peptide generic market. Also, collaboration of pharmaceutical companies with biotechnology fuelling the market growth of peptide therapeutics.
Scope of the Report
The Global Peptide Therapeutics Market is valued at USD 32.1 Billion in the year 2020. The growth of Peptide Therapeutics is directly associated with drug development. New drug discovery and product launch in chronic metabolic disorders would provide fruitful opportunities for Peptide Therapeutics Market. The factors such as surging prevalence of cancer, rising healthcare expenditure, growing incidence of metabolic disorders, increasing geriatric population and accelerating number of approved peptide-based therapeutic drugs will facilitate market growth.
New drug discovery and product launch in chronic metabolic disorders expected to provide potential opportunities to Peptide Therapeutics Market, further supported by factors such as surging prevalence of cancer, rising healthcare expenditure, growing incidence of metabolic disorders, increasing geriatric population and accelerating number of approved peptide-based therapeutic drugs. Over the years, the rising popularity of biologics, such as peptide therapeutics, have led to an evident shift in the focus of the healthcare industry, from traditional small molecule-based interventions to upcoming, albeit complex, family of pharmacological interventions.
The success of peptide therapeutics, so far, can be attributed to their clinical benefits, which include high target specificity, low toxicity and favourable safety profiles. Furthermore, with enhanced technologies, the prospects of the peptide drugs are getting influential day by day and new peptides are being discovered to be developed as peptide drug. Peptide therapeutics is completely different from the traditional methods and may open a new window for finding completely new peptide drugs. Moreover, Peptide gives an opportunity for therapeutics intervention that follows natural pathways hence there has been decline in non-peptide chemically synthesized drug discovery as well as rise in peptide generic market. Also, collaboration of pharmaceutical companies with biotechnology fuelling the market growth of peptide therapeutics.
Scope of the Report
- The report presents the analysis of Peptides Therapeutic market for the historical period 2016-2020 and forecast period of 2021-2026.
- The report analyses the Peptides Therapeutic Market by value (USD Million).
- The report analyses the Peptides Therapeutic Market by Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological, Others).
- The report analyses the Peptides Therapeutic Market Drug Type (Generic, innovative).
- The report analyses the Peptides Therapeutic Market Manufacturing Type (In-house, Outsourced).
- The Global Peptides Therapeutic Market has been analysed By Region (North America, Europe, Asia Pacific and LAMEA), By Country (United States, Canada, Germany, U.K, France, Italy, China, Japan, India and South Korea).
- The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by application, By drug type, by manufacturing type.
- Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis, Sanofi, Pfizer, GlaxoSmithKline, Eli Lily and Company, AstraZeneca Plc., Novo Nordisk, Amgen Inc., Takeda Pharmaceutical Company Limited, Bristol-Mayer Squibb
- Biotechnology Companies
- Healthcare & Pharmaceutical Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
1. REPORT SCOPE AND METHODOLOGY
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
3. PEPTIDES THERAPEUTIC MARKET: PRODUCT OUTLOOK
4. GLOBAL PEPTIDES THERAPEUTIC MARKET: SIZING AND FORECAST
4.1 Global Peptides Therapeutic Market Size, By Value, Year 2016-2026
5. GLOBAL PEPTIDES THERAPEUTIC MARKET SEGMENTATION - BY APPLICATION, BY DRUG TYPE, BY MANUFACTURING TYPE
5.1 Competitive Scenario of Global Peptides Therapeutic Market: By Application
5.1.1 Metabolic - Market Size and Forecast (2016-2026)
5.1.2 Oncology - Market Size and Forecast (2016-2026)
5.1.3 Gastrointestinal - Market Size and Forecast (2016-2026)
5.1.4 Cardiovascular - Market Size and Forecast (2016-2026)
5.1.5 Neurological - Market Size and Forecast (2016-2026)
5.1.6 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Peptides Therapeutic Market: By Drug Type
5.2.1 Generic - Market Size and Forecast (2016-2026)
5.2.2 Innovative- Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Peptides Therapeutic Market: By Manufacturing Type
5.3.1 In-house - Market Size and Forecast (2016-2026)
5.3.2 Outsourced - Market Size and Forecast (2016-2026)
6. GLOBAL PEPTIDES THERAPEUTIC MARKET: REGIONAL ANALYSIS
6.1 Competitive Scenario of Global Peptides Therapeutic Market : By Region
7. NORTH AMERICA PEPTIDES THERAPEUTIC MARKET: AN ANALYSIS (2016-2026)
7.1 North America Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
7.2 North America Peptides Therapeutic Market - Prominent Companies
7.3 Market Segmentation By Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological and Others)
7.4 Market Segmentation By Drug Type (Generic, Innovative)
7.5 Market Segmentation By Manufacturing Type (In-house, Outsourced)
7.6 North America Peptides Therapeutic Market: Country Analysis
7.7 Market Opportunity Chart of North America Peptides Therapeutic Market - By Country, By Value, 2026
7.8 Competitive Scenario of North America Peptides Therapeutic Market: By Country
7.9 United States Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
7.10 United States Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
7.11 Canada Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
7.12 Canada Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
8. EUROPE PEPTIDES THERAPEUTIC MARKET: AN ANALYSIS (2016-2026)
8.1 Europe Peptides Therapeutic Market : Size and Forecast (2016-2026), By Value
8.2 Europe Peptides Therapeutic Market - Prominent Companies
8.3 Market Segmentation By Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological and Others)
8.4 Market Segmentation By Drug Type (Generic, Innovative)
8.5 Market Segmentation By Manufacturing Type (In-house, Outsourced)
8.6 Europe Peptides Therapeutic Market: Country Analysis
8.7 Market Opportunity Chart of Europe Peptides Therapeutic Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Peptides Therapeutic Market: By Country
8.9 Germany Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
8.10 Germany Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
8.11 United Kingdom Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
8.13 France Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
8.14 France Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
8.15 Italy Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
8.16 Italy Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
9. ASIA PACIFIC PEPTIDES THERAPEUTIC MARKET: AN ANALYSIS (2016-2026)
9.1 Asia Pacific Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Peptides Therapeutic Market - Prominent Companies
9.3 Market Segmentation By Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological and Others)
9.4 Market Segmentation By Drug Type (Generic, Innovative)
9.5 Market Segmentation By Manufacturing Type (In-house, Outsourced)
9.6 Asia Pacific Peptides Therapeutic Market: Country Analysis
9.7 Market Opportunity Chart of Asia Pacific Peptides Therapeutic Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Peptides Therapeutic Market: By Country
9.9 China Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
9.10 China Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
9.11 Japan Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
9.12 Japan Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
9.13 India Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
9.14 India Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
9.15 South Korea Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
9.16 South Korea Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
10. GLOBAL PEPTIDES THERAPEUTIC MARKET DYNAMICS
10.1 Drivers
10.2 Restraints
10.3 Trends
11. MARKET ATTRACTIVENESS
11.1 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Application, 2026
11.2 Market Attractiveness Chart of Global Peptides Therapeutic Market - By drug Type, 2026
11.3 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Manufacturing Type, 2026
11.4 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Region, 2026
12. COMPETITIVE LANDSCAPE
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Market Share Analysis
13. COMPANY ANALYSIS
13.1 Novartis
13.2 Sanofi
13.3 Pfizer
13.4 GlaxoSmithkline
13.5 Eli Lily and Company
13.6 AstraZeneca Plc
13.7 Novo Nordisk
13.8 Amgen Inc
13.9 Takeda Pharmaceutical Company Limited
13.10 Bristol-Mayer Squibb
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
3. PEPTIDES THERAPEUTIC MARKET: PRODUCT OUTLOOK
4. GLOBAL PEPTIDES THERAPEUTIC MARKET: SIZING AND FORECAST
4.1 Global Peptides Therapeutic Market Size, By Value, Year 2016-2026
5. GLOBAL PEPTIDES THERAPEUTIC MARKET SEGMENTATION - BY APPLICATION, BY DRUG TYPE, BY MANUFACTURING TYPE
5.1 Competitive Scenario of Global Peptides Therapeutic Market: By Application
5.1.1 Metabolic - Market Size and Forecast (2016-2026)
5.1.2 Oncology - Market Size and Forecast (2016-2026)
5.1.3 Gastrointestinal - Market Size and Forecast (2016-2026)
5.1.4 Cardiovascular - Market Size and Forecast (2016-2026)
5.1.5 Neurological - Market Size and Forecast (2016-2026)
5.1.6 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Peptides Therapeutic Market: By Drug Type
5.2.1 Generic - Market Size and Forecast (2016-2026)
5.2.2 Innovative- Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Peptides Therapeutic Market: By Manufacturing Type
5.3.1 In-house - Market Size and Forecast (2016-2026)
5.3.2 Outsourced - Market Size and Forecast (2016-2026)
6. GLOBAL PEPTIDES THERAPEUTIC MARKET: REGIONAL ANALYSIS
6.1 Competitive Scenario of Global Peptides Therapeutic Market : By Region
7. NORTH AMERICA PEPTIDES THERAPEUTIC MARKET: AN ANALYSIS (2016-2026)
7.1 North America Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
7.2 North America Peptides Therapeutic Market - Prominent Companies
7.3 Market Segmentation By Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological and Others)
7.4 Market Segmentation By Drug Type (Generic, Innovative)
7.5 Market Segmentation By Manufacturing Type (In-house, Outsourced)
7.6 North America Peptides Therapeutic Market: Country Analysis
7.7 Market Opportunity Chart of North America Peptides Therapeutic Market - By Country, By Value, 2026
7.8 Competitive Scenario of North America Peptides Therapeutic Market: By Country
7.9 United States Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
7.10 United States Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
7.11 Canada Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
7.12 Canada Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
8. EUROPE PEPTIDES THERAPEUTIC MARKET: AN ANALYSIS (2016-2026)
8.1 Europe Peptides Therapeutic Market : Size and Forecast (2016-2026), By Value
8.2 Europe Peptides Therapeutic Market - Prominent Companies
8.3 Market Segmentation By Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological and Others)
8.4 Market Segmentation By Drug Type (Generic, Innovative)
8.5 Market Segmentation By Manufacturing Type (In-house, Outsourced)
8.6 Europe Peptides Therapeutic Market: Country Analysis
8.7 Market Opportunity Chart of Europe Peptides Therapeutic Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Peptides Therapeutic Market: By Country
8.9 Germany Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
8.10 Germany Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
8.11 United Kingdom Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
8.13 France Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
8.14 France Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
8.15 Italy Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
8.16 Italy Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
9. ASIA PACIFIC PEPTIDES THERAPEUTIC MARKET: AN ANALYSIS (2016-2026)
9.1 Asia Pacific Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Peptides Therapeutic Market - Prominent Companies
9.3 Market Segmentation By Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological and Others)
9.4 Market Segmentation By Drug Type (Generic, Innovative)
9.5 Market Segmentation By Manufacturing Type (In-house, Outsourced)
9.6 Asia Pacific Peptides Therapeutic Market: Country Analysis
9.7 Market Opportunity Chart of Asia Pacific Peptides Therapeutic Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Peptides Therapeutic Market: By Country
9.9 China Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
9.10 China Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
9.11 Japan Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
9.12 Japan Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
9.13 India Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
9.14 India Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
9.15 South Korea Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
9.16 South Korea Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
10. GLOBAL PEPTIDES THERAPEUTIC MARKET DYNAMICS
10.1 Drivers
10.2 Restraints
10.3 Trends
11. MARKET ATTRACTIVENESS
11.1 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Application, 2026
11.2 Market Attractiveness Chart of Global Peptides Therapeutic Market - By drug Type, 2026
11.3 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Manufacturing Type, 2026
11.4 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Region, 2026
12. COMPETITIVE LANDSCAPE
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Market Share Analysis
13. COMPANY ANALYSIS
13.1 Novartis
13.2 Sanofi
13.3 Pfizer
13.4 GlaxoSmithkline
13.5 Eli Lily and Company
13.6 AstraZeneca Plc
13.7 Novo Nordisk
13.8 Amgen Inc
13.9 Takeda Pharmaceutical Company Limited
13.10 Bristol-Mayer Squibb
TABLES AND FIGURES
Figure 1: Global Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 3: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 4: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 5: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 6: Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 7: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 8: Global Peptides Therapeutic Market- By Application Market Share, 2020 & 2026
Figure 9: Global Peptides Therapeutic Market- By Metabolic , By Value (USD Million), 2016-2026
Figure 10: Global Peptides Therapeutic Market- By Oncology , By Value (USD Million), 2016-2026
Figure 11: Global Peptides Therapeutic Market- By Gastrointestinal, By Value (USD Million), 2016-2026
Figure 12: Global Peptides Therapeutic Market- By Cardiovascular , By Value (USD Million), 2016-2026
Figure 13: Global Peptides Therapeutic Market- By Neurological , By Value (USD Million), 2016-2026
Figure 14: Global Peptides Therapeutic Market- By Others, By Value (USD Million), 2016-2026
Figure 15: Global Peptides Therapeutic Market- By Drug Type Market Share, 2020 & 2026
Figure 16: Global Peptides Therapeutic Market- By Generic, By Value (USD Million), 2016-2026
Figure 17: Global Peptides Therapeutic Market- By Innovative, By Value (USD Million), 2016-2026
Figure 18: Global Peptides Therapeutic Market- By Manufacturing Type Market Share, 2020 & 2026
Figure 19: Global Peptides Therapeutic Market- By In-house, By Value (USD Million), 2016-2026
Figure 20: Global Peptides Therapeutic Market- By Outsourced, By Value (USD Million), 2016-2026
Figure 21: Global Peptides Therapeutic Market- By Region Market Share, 2020 & 2026
Figure 22: North America Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 23: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 24: North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 25: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 26: North America Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 27: North America Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 28: North America Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 29: Market Opportunity Chart of North America Peptides Therapeutic Market- By Country, By Value (Year-2026)
Figure 30: North America Peptides Therapeutic Market- By Country Market Share, 2020 & 2026
Figure 31: United States Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 32: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 33: United State Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 34: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 35: United State Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 36: United State Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 37: United State Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 38: Canada Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 39: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 40: Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 41: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 42: Canada Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 43: Canada Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 44: Canada Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 45: Europe Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 46: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 47: Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 48: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 49: Europe Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 50: Europe Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 51: Europe Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 52: Market Opportunity Chart of Europe Peptides Therapeutic Market- By Country, By Value (Year-2026)
Figure 53: Europe Peptides Therapeutic Market- By Country Market Share, 2020 & 2026
Figure 54: Germany Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 55: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 56: Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 57: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 58: Germany Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 59: Germany Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 60: Germany Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 61: United Kingdom Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 62: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 63: United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 64: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 65: United Kingdom Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 66: United Kingdom Peptides Therapeutic Market- By Drug Type, By Value (USD Millon), 2016-2026
Figure 67: United Kingdom Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 68: France Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 69: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 70: France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 71: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 72: France Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 73: France Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 74: France Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 75: Italy Pharmacy Retail Market Size, By Value, 2016-2026 (USD Billion)
Figure 76: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 77: Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 78: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 79: Italy Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 80: Italy Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 81: Italy Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 82: Asia Pacific Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 83: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 84: Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 85: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 86: Asia Pacific Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 87: Asia Pacific Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 88: Asia Pacific Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 89: Market Opportunity Chart of APAC Peptides Therapeutic Market- By Country, By Value (Year-2026)
Figure 90: APAC Peptides Therapeutic Market- By Country Market Share, 2020 & 2026
Figure 91: China Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 92: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 93: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 94: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 95: China Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 96: China Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 97: China Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 98: Japan Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 99: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 100: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 101: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 102: Japan Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 103: Japan Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 104: Japan Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 105: India Pharmacy Retail Market Size, By Value, 2016-2026 (USD Billion)
Figure 106: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 107: India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 108: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 109: India Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 110: India Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 111: India Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 112: South Korea Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 113: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 114: South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 115: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 116: South Korea Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 117: South Korea Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 118: South Korea Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 119: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Application (Year 2016-2026)
Figure 120: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Drug Type (Year-2026)
Figure 121: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Manufacturing Type (Year 2016-2026)
Figure 122: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Region (Year 2016-2026)
Figure 123: Global Peptides Therapeutic company market share (%), 2020
Figure 134: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 125: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 126: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 127: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 128: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 129: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 130: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 131: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 132: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 133: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 134: Pfizer sales Revenue, By Geographical Segment (%), FY2020
Figure 135: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 136: GlaxoSmithKline Net Profit (USD Million), 2016-2020
Figure 137: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 138: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 139: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Figure 140: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Figure 141: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 142: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
Figure 143: AstraZeneca Sales Revenues, 2016-2020 (USD Million)
Figure 144: AstraZeneca Gross Profit, 2016-2020 (USD Million)
Figure 145: AstraZeneca Plc Sales Revenue Split, By Business Segment (%), FY2020
Figure 146: AstraZeneca Plc Sales Revenue Split, By Geography Segment (%), FY2020
Figure 147: Novo Nordisk Sales Revenues, 2016-2020 (USD Million)
Figure 148: Novo Nordisk Net Profit, 2016-2020 (USD Million)
Figure 149: Novo Nordisk Sales Revenue Split, By Business Segment (%), FY2020
Figure 150: Novo Nordisk Sales Revenue Split, By Geography Segment (%), FY2020
Figure 151: Amgen Inc. Sales Revenues, 2016-2020 (USD Million)
Figure 152: Amgen Inc. Net Income, 2016-2020 (USD Million)
Figure 153: Amgen Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 154: Amgen Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Figure 155: Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
Figure 156: Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
Figure 157: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
Figure 158: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
Figure 159: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Figure 160: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Figure 161: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Figure 162: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
Figure 1: Global Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 3: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 4: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 5: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 6: Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 7: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 8: Global Peptides Therapeutic Market- By Application Market Share, 2020 & 2026
Figure 9: Global Peptides Therapeutic Market- By Metabolic , By Value (USD Million), 2016-2026
Figure 10: Global Peptides Therapeutic Market- By Oncology , By Value (USD Million), 2016-2026
Figure 11: Global Peptides Therapeutic Market- By Gastrointestinal, By Value (USD Million), 2016-2026
Figure 12: Global Peptides Therapeutic Market- By Cardiovascular , By Value (USD Million), 2016-2026
Figure 13: Global Peptides Therapeutic Market- By Neurological , By Value (USD Million), 2016-2026
Figure 14: Global Peptides Therapeutic Market- By Others, By Value (USD Million), 2016-2026
Figure 15: Global Peptides Therapeutic Market- By Drug Type Market Share, 2020 & 2026
Figure 16: Global Peptides Therapeutic Market- By Generic, By Value (USD Million), 2016-2026
Figure 17: Global Peptides Therapeutic Market- By Innovative, By Value (USD Million), 2016-2026
Figure 18: Global Peptides Therapeutic Market- By Manufacturing Type Market Share, 2020 & 2026
Figure 19: Global Peptides Therapeutic Market- By In-house, By Value (USD Million), 2016-2026
Figure 20: Global Peptides Therapeutic Market- By Outsourced, By Value (USD Million), 2016-2026
Figure 21: Global Peptides Therapeutic Market- By Region Market Share, 2020 & 2026
Figure 22: North America Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 23: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 24: North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 25: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 26: North America Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 27: North America Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 28: North America Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 29: Market Opportunity Chart of North America Peptides Therapeutic Market- By Country, By Value (Year-2026)
Figure 30: North America Peptides Therapeutic Market- By Country Market Share, 2020 & 2026
Figure 31: United States Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 32: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 33: United State Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 34: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 35: United State Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 36: United State Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 37: United State Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 38: Canada Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 39: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 40: Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 41: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 42: Canada Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 43: Canada Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 44: Canada Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 45: Europe Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 46: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 47: Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 48: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 49: Europe Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 50: Europe Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 51: Europe Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 52: Market Opportunity Chart of Europe Peptides Therapeutic Market- By Country, By Value (Year-2026)
Figure 53: Europe Peptides Therapeutic Market- By Country Market Share, 2020 & 2026
Figure 54: Germany Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 55: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 56: Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 57: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 58: Germany Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 59: Germany Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 60: Germany Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 61: United Kingdom Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 62: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 63: United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 64: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 65: United Kingdom Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 66: United Kingdom Peptides Therapeutic Market- By Drug Type, By Value (USD Millon), 2016-2026
Figure 67: United Kingdom Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 68: France Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 69: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 70: France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 71: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 72: France Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 73: France Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 74: France Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 75: Italy Pharmacy Retail Market Size, By Value, 2016-2026 (USD Billion)
Figure 76: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 77: Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 78: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 79: Italy Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 80: Italy Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 81: Italy Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 82: Asia Pacific Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 83: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 84: Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 85: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 86: Asia Pacific Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 87: Asia Pacific Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 88: Asia Pacific Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 89: Market Opportunity Chart of APAC Peptides Therapeutic Market- By Country, By Value (Year-2026)
Figure 90: APAC Peptides Therapeutic Market- By Country Market Share, 2020 & 2026
Figure 91: China Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 92: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 93: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 94: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 95: China Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 96: China Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 97: China Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 98: Japan Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 99: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 100: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 101: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 102: Japan Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 103: Japan Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 104: Japan Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 105: India Pharmacy Retail Market Size, By Value, 2016-2026 (USD Billion)
Figure 106: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 107: India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 108: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 109: India Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 110: India Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 111: India Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 112: South Korea Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Figure 113: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 114: South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 115: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 116: South Korea Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Figure 117: South Korea Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 118: South Korea Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
Figure 119: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Application (Year 2016-2026)
Figure 120: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Drug Type (Year-2026)
Figure 121: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Manufacturing Type (Year 2016-2026)
Figure 122: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Region (Year 2016-2026)
Figure 123: Global Peptides Therapeutic company market share (%), 2020
Figure 134: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 125: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 126: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 127: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 128: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 129: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 130: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 131: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 132: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 133: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 134: Pfizer sales Revenue, By Geographical Segment (%), FY2020
Figure 135: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 136: GlaxoSmithKline Net Profit (USD Million), 2016-2020
Figure 137: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 138: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 139: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Figure 140: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Figure 141: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 142: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
Figure 143: AstraZeneca Sales Revenues, 2016-2020 (USD Million)
Figure 144: AstraZeneca Gross Profit, 2016-2020 (USD Million)
Figure 145: AstraZeneca Plc Sales Revenue Split, By Business Segment (%), FY2020
Figure 146: AstraZeneca Plc Sales Revenue Split, By Geography Segment (%), FY2020
Figure 147: Novo Nordisk Sales Revenues, 2016-2020 (USD Million)
Figure 148: Novo Nordisk Net Profit, 2016-2020 (USD Million)
Figure 149: Novo Nordisk Sales Revenue Split, By Business Segment (%), FY2020
Figure 150: Novo Nordisk Sales Revenue Split, By Geography Segment (%), FY2020
Figure 151: Amgen Inc. Sales Revenues, 2016-2020 (USD Million)
Figure 152: Amgen Inc. Net Income, 2016-2020 (USD Million)
Figure 153: Amgen Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 154: Amgen Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Figure 155: Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
Figure 156: Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
Figure 157: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
Figure 158: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
Figure 159: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Figure 160: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Figure 161: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Figure 162: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
